“…In the last 15 years, the rare nature of PXA has resulted in a slowly growing literature restricted to well-documented case reports of classic examples (35, 63), classic examples with unusual clinical presentation/course (2, 8, 12, 21, 40, 48, 67) or in uncommon locations (3, 11, 19, 27, 45, 55, 60, 72), rare morphological variants (9, 18, 52, 54, 59, 65, 70), biphasic combined/collision tumors (1, 6, 15, 16, 25, 28, 31, 51, 61, 73), as well as a few small series (17, 20, 29, 38, 39, 42, 47, 53, 58, 62) and reviews (32, 42, 64, 68). Currently, WHO grading of so-called “PXA-AF” remains undefined, and it is still unclear whether these rare tumors should be termed “anaplastic” (WHO grade III).…”